Supernus Pharmaceuticals(SUPN) - 2024 Q3 - Quarterly Results

Filing Information Administrative details of Supernus Pharmaceuticals, Inc.'s Form 8-K filing, including registrant and filing date - Supernus Pharmaceuticals, Inc. is the registrant[1] - The filing is a Current Report on Form 8-K[1] - The report date is October 21, 2024[1] Item 2.02 Results of Operations and Financial Condition Supernus Pharmaceuticals, Inc. announced the Q3 2024 results release date and details for the conference call and webcast - Q3 2024 results are expected after market close on Monday, November 4, 2024[2] - A conference call and webcast to discuss Q3 2024 results is scheduled for November 4, 2024, at 4:30 p.m. E.T.[2] - A press release dated October 21, 2024, is furnished as Exhibit 99.1[2] Item 9.01 Financial Statements and Exhibits This section lists the exhibits accompanying the Form 8-K filing, including a press release and Inline XBRL cover page - Exhibit 99.1 is the press release dated October 21, 2024, filed pursuant to Item 2.02[2] - Exhibit 104 is the Inline XBRL formatted cover page of this Current Report on Form 8-K[2] Signatures This section formally attests to the report's accuracy and authorization by a Supernus Pharmaceuticals, Inc. officer - The signatory is Timothy C. Dec, Senior Vice President and Chief Financial Officer[4] - The signature date is October 21, 2024[4]